Replies to post #771432 on NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

So where you are getting the idea that Iovance is performing badly in revenue is beyond me. If I had to guess its wishful thinking

Likely it's conflating the downgraded revenue guidance from IOVA (which retail has reacted very strongly against) and the low share price that reflects more lack of confidence in the management of the company than in the therapeutic approach.

I don't see why TIL therapy isn't being celebrated here as a testament to the possibilities of cell therapy, rather than as some kind of indictment of NWBO's approach to cell therapy.